Experimental Animal Division

T cell activation is controlled by a balance between the positive and negative signals that are transmitted between antigen-presenting cells and T cells. Programmed cell death-1 (PD-1, Pdcd1) is a co-receptor expressed in T cells that provides feedback inhibition. The ligands for PD-1, called PD-L1 (B7-H1) and PD-L2 (B7-DC), are expressed in B cells, T cells, macrophages, dendritic cells, and in a variety of tissues [1]. Studies on knockout mice have reported a significant role for PD-1 in the autoimmune response. Pdcd1-knockout mice develop lupus-like glomerulonephritis and arthritis on the C57BL/6N background [2], autoimmune dilated cardiomyopathy [3] and gastritis [4] on the BALB/cCr background, sub-acute type 1 diabetes mellitus on the NOD/Shi background [5], and lethal myocarditis on the MRL background [6]. It should be noted that the incidence of autoimmune dilated cardiomyopathy on the BALB/cCr background differs across generations of backcrossing. Approximately 30% of mice at N10 (RBRC00903) develop autoimmune dilated cardiomyopathy, while this is rarely observed in mice at N12 (RBRC00904) and N20 (RBRC02363). Mice at N20 are especially useful when autoimmune dilated cardiomyopathy should be avoided.

PD-1 also plays critical roles in the regulation of the immune response to cancer, allergy, and chronic viral infection. Indeed, large clinical trials have shown that antibodies blocking PD-1 or PD-L1 are likely to provide a new benchmark for antitumor activity in immunotherapy [7]. Pdcd1-deficient mice provide the opportunity to investigate the PD-1-mediated signaling pathway and to develop novel therapies against autoimmune diseases, cancer, infectious diseases, allergic diseases, and other common diseases.